These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38281822)

  • 1. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Eldredge JA; Oliver MR; Ooi CY
    Paediatr Respir Rev; 2024 Jun; 50():54-61. PubMed ID: 38281822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis.
    Akshintala VS; Kamal A; Faghih M; Cutting GR; Cebotaru L; West NE; Jennings MT; Dezube R; Whitcomb DC; Lechtzin N; Merlo CA; Singh VK
    Pancreatology; 2019 Dec; 19(8):1023-1026. PubMed ID: 31611131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
    Mitchell RM; Jones AM; Barry PJ
    Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease.
    van de Peppel IP; Bertolini A; Jonker JW; Bodewes FAJA; Verkade HJ
    Curr Opin Pulm Med; 2017 Nov; 23(6):562-569. PubMed ID: 28837442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 13. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
    Edmondson C; Course CW; Doull I
    Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
    Egan ME
    Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 19. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.